Attorney Docket No. CST-138 CIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FIRST-NAMED INVENTOR:

Box PATENT APPLICATION Assistant Commissioner for Patents

Washington, D.C. 20231

Date of Deposit: November 13, 2001

Comb et al.

ASSIGNEE:

CELL SIGNALING TECHNOLOGY, INC.

FOR:

PRODUCTION OF MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT

ANTIBODIES USING PEPTIDE LIBRARIES AS ANTIGENS

November 13, 2001

Beverly, Massachusetts



REQUEST FOR FILING A CONTINUING UTILITY APPLICATION UNDER 37 C.F.R. §1.53(b)

1.	This is a request for filing a continuing application under 37 C.F.R. §1.53(b). (Check the appropriate boxes and supply the requisite information)				
	This a	pplication is a:			
	Co.	ntinuation; Divisional; Continuation-in-part of prior application U.S.S.N. 09/535,364, filed 24, 2000, and U.S.S.N. 09/148,712, filed September 4, 1998, both presently pending.			
2.	Priorit	y to the above application(s) is claimed under:			
		35 U.S.C. §120 Prior application information (for both): Examiner: T. Wessendorf; Group Art Unit: 1627.			
		35 U.S.C. §119			
		Priority of application Serial No, filed on in is claimed under 35 U.S.C. §119.			
•		The certified copy has been filed in prior application U.S.S.N/, on [Date]. The certified copy will follow.			
APPL	ICATIO	ON ELEMENTS:			
3.	\boxtimes	Specification and Drawings (Total pages: 113) (excluding application cover sheet):			
		Specification (w/claims, abstract) (90 pages); Claims (10 pages); Abstract (1 page); and Drawings: 23 sheets; FIGS. 1A-29.			
		☐ Formal ☐ Informal			

FIRST-NAMED INVENTOR:

Comb et al. Request for Continuing Nonprovisional Application (37 C.F.R. §1.53(b))

		•		
4.		 Nucleotide and/or Amino Acid Sequence Submission: Computer-readable Copy: The computer-readable copy of the Sequence Listing in the instant application is to be identical to that filed in application U.S.S.N/, filed [filing date]. In accordance with 37 C.F.R. § 1.821(e), please use the computer-readable form filed in that application as the computer-readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application. Paper Copy: A paper copy of the Sequence Listing is included in the copy of the originally-filed specification of the instant application (47 Pages) Statement: A Submission of Paper/Computer Readable Sequence Listing with statement that the contents of the two are identical is enclosed herewith (2 Pages) 		
5.		Microfiche Computer Program (Appendix)		
6.	(a) (b)	Oath or Declaration (Total pages: 3): Newly executed (original) Copy from a prior application (37 C.F.R. §1.63(d))		
7.		Incorporation by Reference (can use if Box 6(b) is checked)		
: -		The entire Disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 6(b), is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.		
ASSI	ERTION	OF ENTITLEMENT TO SMALL ENTITY STATUS (37 C.F.R. §1.27(c)(1)):		
8.		The undersigned attorney hereby asserts that Applicants' assignee is small business concern and is therefore entitled to small entity status.		
ACC	OMPAN	YING APPLICATION PARTS:		
9.		English Translation Document (if applicable)		
10.		Information Disclosure Statement (IDS) Copy of IDS (5 pgs.) and PTO-1449 (4 pgs., in duplicate) Copies of references cited Copies of relevant copending applications (unless relied on for §120 effective priority) (37 C.F.R. §1.98(d)(1))		
11.	Fee Cal	culation:		
		A Preliminary Amendment is enclosed herewith. Please enter the claim amendments prior to		

calculating the filing fee.

ļ.

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. 1.16(a) \$710.00
Total Claims (37 C.F.R. 1.16(c))	73	- 20 =	53	\$ 18.00	954.00
Independent Claims (37 C.F.R. 1.16(b))	20	- 3 =	17	\$80.00	1360.00
Multiple Dependent Claim(s), if any (37 C.F.R. 1.16(d))	Yes			\$270.00	270.00
SUBTOTAL: Reduction by 50% for filing by small entity: TOTAL FEE:		OTAL:	<u>\$2584.00</u>		
		- <u>\$1292.00</u>			
		FEE:	<u>\$1292.00</u>		

12.	\boxtimes	A check #028280 in the amount of \$1292.00 is enclosed.		
13.		Deletion of Inventor(s) This application is filed by fewer than all the inventors named in the prior application,		
		37 C.F.R. §1.53(d)(4).		
		DELETE the following inventor(s) named in the prior nonprovisional application: The inventor(s) to be deleted are set forth on a separate sheet attached hereto.		
14.		The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 50-1774, Ref. No. CST-138 CIP2: Fees required under 37 C.F.R. §1.16; Fees required under 37 C.F.R. §1.17; Fees required under 37 C.F.R. §1.18.		
15.	\boxtimes	Return Receipt Postcard Enclosed.		
` 16.		Other Documents Enclosed:		

Dated: 11/13/01

Respectfully submitted,

James Gregory Cullem, Reg. No. 43,569
Intellectual Property Counsel
CELL SIGNALING TECHNOLOGY, INC.
166B Cummings Center
Beverly, Massachusetts 01915
Tel: (978) 867-2311

Fax: (978) 867-2400

Express Mail Label No. EE742586909US Date of Deposit: November 13, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Comb et al.

ASSIGNEE:

CELL SIGNALING TECHNOLOGY, INC.

For:

PRODUCTION OF MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT ANTIBODIES

USING PEPTIDE LIBRARIES AS ANTIGENS

November 13, 2001 Beverly, Massachusetts

Assistant Commissioner for Patents Washington, D.C. 20231

Attached hereto for filing in the above-identified patent application is/are:

- X Transmittal Letter (w/duplicate) (2 pages);
- X Request for Filing a Continuing Utility Application (3 pages);
- X Specification (90 pages);
- \boxtimes Drawings (23 sheets);
- \boxtimes Original Combined Declaration and Power of Attorney (3 pages);
- \boxtimes Paper Copy of Sequence Listing (47 pages);
- \boxtimes Disk Copy of Sequence Listing (1 disk);
- \boxtimes Submission of Paper Copy and/or Computer-Readable Copy of Sequence Listing for Invention Containing Nucleotide and/or Amino Acid (2 pages);;
- X Information Disclosure Statement (5 pages);
- \boxtimes IDS Form PTO-1449 (w/duplicate) (8 sheets);
- \boxtimes Copies of IDS References CS, CT-CX (6 refs.);
- \boxtimes Check No. 028280 in the amount of \$1,292.00;
- \boxtimes Return Postcard.

Respectfully submitted,

James Gregory Cullem, Reg. No. 43,569

Intellectual Property Counsel

CELL SIGNALING TECHNOLOGY, INC.

166B Cummings Center

Beverly, Massachusetts 01915

Tel: (978) 867-2311 Fax: (978) 867-2400 Express Mail Label No.: EE742586909US

Date of Deposit: November 13, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Comb et al.		
ASSIGNEE:	CELL SIGNALING TECHNOL	OGY, INC.	
SERIAL NUMBER:	Not yet assigned	EXAMINER:	Not yet assigned
FILING DATE:	Herewith	ART UNIT:	Not yet assigned
For:	PRODUCTION OF MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT ANTIBODIES USING PEPTIDE LIBRARIES AS ANTIGENS		

November 13, 2001 Beverly, Massachusetts

Box SEQUENCE

Assistant Commissioner for Patents Washington, D.C. 20231

SUBMISSION OF PAPER COPY AND/OR COMPUTER-READABLE COPY OF SEQUENCE LISTING FOR INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

1.		This paper is in response to the Patent Office letter dated			
		A copy of the Patent Office letter is enclosed.			
		Note: If these papers are filed before the Patent Office letter is mailed, the adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of the invention, the filing date on the Express Mail Label, the USSN from the return postcard or the attorney's docket number must be added.			
	\boxtimes	This paper is in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures.			
	\boxtimes	This paper is being filed simultaneously with a request for filing of a new patent application.			
2.	Subm	Submitted herewith are:			
		A Preliminary Amendment directing entry of the Sequence Listing into the specification;			
	\boxtimes	a paper copy of the Sequence Listing for the above-identified patent application with each sequence assigned a separate identifier; and			
	\boxtimes	a copy of the Sequence Listing in computer-readable form for the above-identified patent application.			

APPLICANTS:

Comb et al.

U.S.S.N.:

Not yet assigned (Attorney Docket No. CST-138 CIP2)

3.	Statement:
J.	Statement.

I hereby state that: (complete applicable items – A, B and/or C)

- A. The content of the paper and computer-readable copies of the Sequence Listing submitted herewith are the same.
- B. The content of the computer-readable copy of the Sequence Listing submitted herewith is the same as the Sequence Listing appearing at the end of the originally-filed specification.
- C. This submission includes no new matter.

Applicants believe that no fee is required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-1774, Ref. No. CST-138 CIP2.

Respectfully submitted,

James Gregory Cullem, Reg. No. 43,569

Intellectual Property Counsel

CELL SIGNALING TECHNOLOGY, INC.

166B Cummings Center Beverely, MA 01915

(978) 867-2311

Dated: 11/13/01